Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 170

1.

Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with Increased blasts (<10%) or with other types of disease progression.

Geyer JT, Margolskee E, Krichevsky SA, Cattaneo D, Boiocchi L, Ronchi P, Lunghi F, Scandura JM, Ponzoni M, Hasserjian RP, Gianelli U, Iurlo A, Orazi A.

Haematologica. 2019 Sep 19. pii: haematol.2019.230193. doi: 10.3324/haematol.2019.230193. [Epub ahead of print]

2.

Illuminating neutrophilic myeloid neoplasms.

Hasserjian RP.

Blood. 2019 Sep 12;134(11):846-848. doi: 10.1182/blood.2019002302. No abstract available.

PMID:
31515226
3.

Premalignant Clonal Hematopoietic Proliferations.

Nardi V, Kuo FC, Hasserjian RP.

Am J Clin Pathol. 2019 Aug 1;152(3):347-358. doi: 10.1093/ajcp/aqz079.

PMID:
31305863
4.

Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias).

Hasserjian RP, Kelley TW, Weinberg OK, Morgan EA, Fend F.

Am J Clin Pathol. 2019 Aug 1;152(3):302-321. doi: 10.1093/ajcp/aqz069.

PMID:
31263893
5.

Emerging patterns in clonal haematopoiesis.

Capo-Chichi JM, Michaels P, Tremblay-Le May R, Abelson S, Hasserjian RP, Xia D.

J Clin Pathol. 2019 Jul;72(7):453-459. doi: 10.1136/jclinpath-2019-205851. Epub 2019 Jun 4. Review.

PMID:
31164443
6.

High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia.

Patel SS, Pinkus GS, Ritterhouse LL, Segal JP, Dal Cin P, Restrepo T, Harris MH, Stone RM, Hasserjian RP, Weinberg OK.

Am J Hematol. 2019 Aug;94(8):921-928. doi: 10.1002/ajh.25544. Epub 2019 Jun 17.

PMID:
31148220
7.

Introduction.

Weinberg OK, Kuo F, Hasserjian RP.

Am J Clin Pathol. 2019 Aug 1;152(3):254-257. doi: 10.1093/ajcp/aqz047. No abstract available.

PMID:
31141600
8.

Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms.

Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT, Xu ML, Prebet T, Mason EF, Seegmiller AC, Morgan EA, Steensma DP, Winer ES, Wong WJ, Hasserjian RP, Weinberg OK.

Blood Adv. 2019 May 14;3(9):1540-1545. doi: 10.1182/bloodadvances.2019000090.

9.

Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures.

Wong WJ, Baltay M, Getz A, Fuhrman K, Aster JC, Hasserjian RP, Pozdnyakova O.

PLoS One. 2019 May 9;14(5):e0216810. doi: 10.1371/journal.pone.0216810. eCollection 2019.

10.

Clinical, immunophenotypic, and genomic findings of acute undifferentiated leukemia and comparison to acute myeloid leukemia with minimal differentiation: a study from the bone marrow pathology group.

Weinberg OK, Hasserjian RP, Baraban E, Ok CY, Geyer JT, Philip JKSS, Kurzer JH, Rogers HJ, Nardi V, Stone RM, Garcia JS, Hsi ED, Bagg A, Wang SA, Orazi A, Arber DA.

Mod Pathol. 2019 Sep;32(9):1373-1385. doi: 10.1038/s41379-019-0263-3. Epub 2019 Apr 18.

PMID:
31000771
11.

Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.

Boiocchi L, Hasserjian RP, Pozdnyakova O, Wong WJ, Lennerz JK, Le LP, Dias-Santagata D, Iafrate AJ, Hobbs GS, Nardi V.

Hum Pathol. 2019 Apr;86:1-11. doi: 10.1016/j.humpath.2018.11.022. Epub 2018 Dec 27.

PMID:
30594750
12.

The current approach to the diagnosis of myelodysplastic syndromes.

Weinberg OK, Hasserjian RP.

Semin Hematol. 2019 Jan;56(1):15-21. doi: 10.1053/j.seminhematol.2018.05.015. Epub 2018 Jun 23. Review.

PMID:
30573039
13.

Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.

Tang G, Sydney Sir Philip JK, Weinberg O, Tam W, Sadigh S, Lake JI, Margolskee EM, Rogers HJ, Miranda RN, Bueso-Ramos C C, Hsi ED, Orazi A, Hasserjian RP, Arber DA, Bagg A, Wang SA.

Mod Pathol. 2019 Apr;32(4):490-498. doi: 10.1038/s41379-018-0165-9. Epub 2018 Nov 6.

PMID:
30401948
14.

Follicular Dendritic Cell Sarcoma With Indolent T-Lymphoblastic Proliferation Is Associated With Paraneoplastic Autoimmune Multiorgan Syndrome.

Walters M, Pittelkow MR, Hasserjian RP, Harris NL, Macon WR, Kurtin PJ, Rech KLG.

Am J Surg Pathol. 2018 Dec;42(12):1647-1652. doi: 10.1097/PAS.0000000000001158.

PMID:
30222603
15.

tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish.

Ignatius MS, Hayes MN, Moore FE, Tang Q, Garcia SP, Blackburn PR, Baxi K, Wang L, Jin A, Ramakrishnan A, Reeder S, Chen Y, Nielsen GP, Chen EY, Hasserjian RP, Tirode F, Ekker SC, Langenau DM.

Elife. 2018 Sep 7;7. pii: e37202. doi: 10.7554/eLife.37202.

16.

Composite chronic myeloid leukemia and essential thrombocythemia with BCR-ABL1 fusion and CALR mutation.

Xia D, Hsi ED, Dal Cin P, Hasserjian RP.

Am J Hematol. 2019 Apr;94(4):504-505. doi: 10.1002/ajh.25249. Epub 2018 Sep 21. No abstract available.

PMID:
30105753
17.

Myelodysplastic Syndrome Updated.

Hasserjian RP.

Pathobiology. 2019;86(1):7-13. doi: 10.1159/000489702. Epub 2018 Jul 24. Review.

PMID:
30041243
18.

Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.

Hebeda KM, Tzankov A, Boudova L, Saft L, Hasserjian RP, de Boer M, Fend F, Orazi A, Leguit R.

Pathobiology. 2019;86(1):62-75. doi: 10.1159/000489678. Epub 2018 Jul 6.

19.

Diagnostic algorithm for lower-risk myelodysplastic syndromes.

Mufti GJ, McLornan DP, van de Loosdrecht AA, Germing U, Hasserjian RP.

Leukemia. 2018 Aug;32(8):1679-1696. doi: 10.1038/s41375-018-0173-2. Epub 2018 Jun 26. Review.

PMID:
29946191
20.

High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.

Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP 3rd, Chen YA, Fathi AT, Graubert TA, Brunner AM, Wadleigh M, Stone RM, DeAngelo DJ, Nardi V, Hasserjian RP, Weinberg OK.

Blood. 2018 Jun 21;131(25):2816-2825. doi: 10.1182/blood-2018-01-828467. Epub 2018 May 3.

21.

A reevaluation of erythroid predominance in Acute Myeloid Leukemia using the updated WHO 2016 Criteria.

Margolskee E, Mikita G, Rea B, Bagg A, Zuo Z, Sun Y, Goswami M, Wang SA, Oak J, Arber DA, Allen MB, George TI, Rogers HJ, Hsi E, Hasserjian RP, Orazi A.

Mod Pathol. 2018 Jun;31(6):873-880. doi: 10.1038/s41379-018-0001-2. Epub 2018 Feb 5.

22.

Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities.

Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP.

Haematologica. 2018 Apr;103(4):626-633. doi: 10.3324/haematol.2017.181842. Epub 2018 Jan 11.

23.

A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.

Mason EF, Kuo FC, Hasserjian RP, Seegmiller AC, Pozdnyakova O.

Am J Hematol. 2018 Aug;93(4):504-510. doi: 10.1002/ajh.25018. Epub 2018 Jan 25.

24.

Changes in the World Health Organization 2016 classification of myeloid neoplasms everyone should know.

Hasserjian RP.

Curr Opin Hematol. 2018 Mar;25(2):120-128. doi: 10.1097/MOH.0000000000000404. Review.

PMID:
29256927
25.

JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms.

Wong WJ, Hasserjian RP, Pinkus GS, Breyfogle LJ, Mullally A, Pozdnyakova O.

Haematologica. 2018 Feb;103(2):e63-e68. doi: 10.3324/haematol.2017.178988. Epub 2017 Nov 16. No abstract available.

26.

Myelodysplastic Syndrome, Unclassifiable (MDS-U) With 1% Blasts Is a Distinct Subgroup of MDS-U With a Poor Prognosis.

Margolskee E, Hasserjian RP, Hassane D, Tam W, Mathew S, Ok CY, Wang SA, Oak J, Arber DA, Orazi A.

Am J Clin Pathol. 2017 Jul 1;148(1):49-57. doi: 10.1093/ajcp/aqx043.

PMID:
28927162
27.

Ring chromosome in myeloid neoplasms is associated with complex karyotype and disease progression.

Rosenbaum MW, Pozdnyakova O, Geyer JT, Dal Cin P, Hasserjian RP.

Hum Pathol. 2017 Oct;68:40-46. doi: 10.1016/j.humpath.2017.08.009. Epub 2017 Aug 24.

PMID:
28842184
28.

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.

Kvasnicka HM, Orazi A, Thiele J, Barosi G, Bueso-Ramos CE, Vannucchi AM, Hasserjian RP, Kiladjian JJ, Gianelli U, Silver R, Mughal TI, Barbui T.

Am J Hematol. 2017 Oct;92(10):1062-1067. doi: 10.1002/ajh.24837. Epub 2017 Jul 29.

29.

FOXP3-stained image analysis for follicular lymphoma: Optimal adaptive thresholding with maximal nucleus coverage.

Senaras C, Pennell M, Chen W, Sahiner B, Shana'ah A, Louissaint A, Hasserjian RP, Lozanski G, Gurcan MN.

Proc SPIE Int Soc Opt Eng. 2017 Feb 11;10140. pii: 101400E. doi: 10.1117/12.2255671. Epub 2017 Mar 1.

30.

Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.

Geyer JT, Tam W, Liu YC, Chen Z, Wang SA, Bueso-Ramos C, Oak J, Arber DA, Hsi E, Rogers HJ, Levinson K, Bagg A, Hassane DC, Hasserjian RP, Orazi A.

Mod Pathol. 2017 Sep;30(9):1213-1222. doi: 10.1038/modpathol.2017.45. Epub 2017 May 26.

31.

Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.

Wang SA, Hasserjian RP, Tam W, Tsai AG, Geyer JT, George TI, Foucar K, Rogers HJ, Hsi ED, Rea BA, Bagg A, Bueso-Ramos CE, Arber DA, Verstovsek S, Orazi A.

Haematologica. 2017 Aug;102(8):1352-1360. doi: 10.3324/haematol.2017.165340. Epub 2017 May 11.

32.

Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22): A Bone Marrow Pathology Group Multicenter Study.

Rogers HJ, Hsi ED, Tang G, Wang SA, Bueso-Ramos CE, Lubin D, Morrissette JJ, Bagg A, Cherukuri DP, George TI, Peterson L, Liu YC, Mathew S, Orazi A, Hasserjian RP.

Am J Clin Pathol. 2017 Apr 1;147(4):411-419. doi: 10.1093/ajcp/aqx020.

PMID:
28375434
33.

NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification.

Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP.

Am J Hematol. 2017 Jul;92(7):E123-E124. doi: 10.1002/ajh.24739. Epub 2017 May 26. No abstract available.

34.

Initial Diagnostic Workup of Acute Leukemia: Guideline From the College of American Pathologists and the American Society of Hematology.

Arber DA, Borowitz MJ, Cessna M, Etzell J, Foucar K, Hasserjian RP, Rizzo JD, Theil K, Wang SA, Smith AT, Rumble RB, Thomas NE, Vardiman JW.

Arch Pathol Lab Med. 2017 Oct;141(10):1342-1393. doi: 10.5858/arpa.2016-0504-CP. Epub 2017 Feb 22.

PMID:
28225303
35.

Prognostic Significance of Residual Acute Myeloid Leukemia in Bone Marrow Samples Taken Prior to Allogeneic Hematopoietic Cell Transplantation.

Kovach AE, Brunner AM, Fathi AT, Chen YB, Hasserjian RP.

Am J Clin Pathol. 2017 Jan 1;147(1):50-59. doi: 10.1093/ajcp/aqw203.

PMID:
28108471
36.

Case 37-2016. An 86-Year-Old Woman with Leukocytosis and Splenomegaly.

Fathi AT, Graubert TA, Kulkarni NM, Kuo FC, Hasserjian RP.

N Engl J Med. 2016 Dec 8;375(23):2273-2282. No abstract available.

PMID:
27959687
37.

Molecular testing for JAK2, MPL, and CALR in myeloproliferative neoplasms.

Xia D, Hasserjian RP.

Am J Hematol. 2016 Dec;91(12):1277-1280. doi: 10.1002/ajh.24578. Review.

38.

Primary lymphoma of bone in the pediatric and young adult population.

Chisholm KM, Ohgami RS, Tan B, Hasserjian RP, Weinberg OK.

Hum Pathol. 2017 Feb;60:1-10. doi: 10.1016/j.humpath.2016.07.028. Epub 2016 Aug 20.

PMID:
27554207
39.

Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.

Wang SA, Patel KP, Pozdnyakova O, Peng J, Zuo Z, Dal Cin P, Steensma DP, Hasserjian RP.

Mod Pathol. 2016 Oct;29(10):1221-31. doi: 10.1038/modpathol.2016.118. Epub 2016 Jul 15.

40.

The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.

Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR.

Am J Hematol. 2016 Oct;91(10):E436-41. doi: 10.1002/ajh.24485. Epub 2016 Aug 4.

41.

Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category.

Weinberg OK, Hasserjian RP, Li B, Pozdnyakova O.

J Clin Pathol. 2017 Feb;70(2):109-115. doi: 10.1136/jclinpath-2016-203863. Epub 2016 Jul 7.

PMID:
27387988
42.

Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations.

Louissaint A Jr, Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D, Roth CG, Paxton CN, Kim S, Namgyal C, Morin R, Morgan EA, Neuberg DS, South ST, Harris MH, Hasserjian RP, Hochberg EP, Garraway LA, Harris NL, Weinstock DM.

Blood. 2016 Aug 25;128(8):1093-100. doi: 10.1182/blood-2015-12-682591. Epub 2016 Jun 20.

43.

Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified.

Wang SA, Tam W, Tsai AG, Arber DA, Hasserjian RP, Geyer JT, George TI, Czuchlewski DR, Foucar K, Rogers HJ, Hsi ED, Bryan Rea B, Bagg A, Dal Cin P, Zhao C, Kelley TW, Verstovsek S, Bueso-Ramos C, Orazi A.

Mod Pathol. 2016 Aug;29(8):854-64. doi: 10.1038/modpathol.2016.75. Epub 2016 May 13.

44.

Small-cell predominant extranodal NK/T cell lymphoma, nasal type: clinicopathological analysis of a series of cases diagnosed in a Western population.

McKelvie PA, Climent F, Krings G, Hasserjian RP, Abramson JS, Pilch BZ, Harris NL, Ferry JA, Zukerberg LR, Sohani AR.

Histopathology. 2016 Oct;69(4):667-79. doi: 10.1111/his.12990. Epub 2016 Jun 21.

PMID:
27144366
45.

Pure Erythroid Leukemia and Erythroblastic Sarcoma Evolving From Chronic Myeloid Neoplasms.

Li H, Hasserjian RP, Kroft SH, Harrington AM, Wheaton SE, Pildain A, Ewalt MD, Gratzinger D, Hosking P, Olteanu H.

Am J Clin Pathol. 2016 Apr;145(4):538-51. doi: 10.1093/ajcp/aqw033. Epub 2016 Apr 22.

PMID:
27124944
46.

Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Nardi V, Hasserjian RP.

Surg Pathol Clin. 2016 Mar;9(1):143-63. doi: 10.1016/j.path.2015.10.004. Review.

PMID:
26940274
47.

Reclassifying myelodysplastic syndromes: what's where in the new WHO and why.

Arber DA, Hasserjian RP.

Hematology Am Soc Hematol Educ Program. 2015;2015:294-8. doi: 10.1182/asheducation-2015.1.294. Review.

PMID:
26637736
48.

Diagnostic Yield of CT-Guided Percutaneous Transthoracic Needle Biopsy for Diagnosis of Anterior Mediastinal Masses.

Petranovic M, Gilman MD, Muniappan A, Hasserjian RP, Digumarthy SR, Muse VV, Sharma A, Shepard JA, Wu CC.

AJR Am J Roentgenol. 2015 Oct;205(4):774-9. doi: 10.2214/AJR.15.14442.

PMID:
26397325
49.

Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Platt MY, Fathi AT, Borger DR, Brunner AM, Hasserjian RP, Balaj L, Lum A, Yip S, Dias-Santagata D, Zheng Z, Le LP, Graubert TA, Iafrate AJ, Nardi V.

J Mol Diagn. 2015 Nov;17(6):661-8. doi: 10.1016/j.jmoldx.2015.06.004. Epub 2015 Aug 30.

50.

Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.

Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Wang SA.

Leuk Lymphoma. 2016;57(4):812-9. doi: 10.3109/10428194.2015.1079318. Epub 2016 Mar 4.

PMID:
26293512

Supplemental Content

Loading ...
Support Center